Search Within

Carl Ola Landgren

Formats
  1. Meeting Abstract (155)
  2. Journal Article (151)
  3. Review (14)
  4. Research Letter (7)
  5. Book Section (3)
  6. Correspondence (2)
  7. Guidelines (2)
  8. Conference Paper (1)
  9. Editorial (1)
Groups
  1. Center for Hematologic Malignancies (336)
  2. Department of Medicine (336)
  3. Hematologic Malignancies Research (336)
  4. Hematologic Malignancies, Division of (336)
  5. Myeloma (336)
  6. Survivorship Research (132)

More Groups

People
  1. Neha Korde (106)
  2. Sham Mailankody (91)
  3. Alexander Lesokhin (83)
  4. Malin Hultcrantz (81)
  5. Hani Hassoun (77)
  6. Sergio Giralt (73)

More People

Years
  1. 2023 (2)
  2. 2022 (4)
  3. 2021 (21)
  4. 2020 (52)
  5. 2019 (56)
  6. 2018 (51)

More Years

Publications
  1. Blood (102)
  2. Haematologica (25)
  3. Clinical Lymphoma, Myeloma and Leukemia (21)
  4. Leukemia and Lymphoma (16)
  5. Biology of Blood and Marrow Transplantation (13)
  6. Blood Cancer Journal (10)

More Publications

Publishers
  1. American Society of Hematology (109)
  2. Elsevier Inc. (45)
  3. Nature Publishing Group (29)
  4. Ferrata Storti Foundation (25)
  5. Taylor & Francis Group (17)
  6. American Association for Cancer Research (15)

More Publishers

Results (336)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • VRd versus KRd safety profiles in newly diagnosed multiple myeloma patients using real-world evidence data from a single institution: VRd has high rates of chronic neuropathy, and KRd has low rates of cardiopulmonary or renal toxicities when using optimized IV fluid management coupled with baseline cardiac workup
    Meeting Abstract

    Tan, C.; Diamond, B.; Hultcrantz, M.; Korde, N.; Lesokhin, A. M.; Mailankody, S.; Hassoun, H.; Shah, U. A.; Lu, S. X.; Patel, D.; more...
    Blood (2020)

    Fulltext@MSK | Save
  • Diabetes mellitus and risk of plasma cell and lymphoproliferative disorders: A population based study including 94,579 cases and 368,348 matched controls
    Meeting Abstract

    Shah, U. A.; Rögnvaldsson, S.; Derkach, A.; Björkholm, M.; Turesson, I.; David, Y.; Hultcrantz, M.; Tan, C.; Hassoun, H.; Korde, N.; more...
    Blood (2020)

    Fulltext@MSK | Save
  • A pilot study evaluating lenalidomide and CC-486 in combination with radiotherapy for patients with plasmacytoma (LENAZART study)
    Meeting Abstract

    Shah, U. A.; Werner, K.; Tavitian, E.; Devlin, S.; Mailankody, S.; Korde, N.; Hultcrantz, M.; Tan, C.; Lu, S. X.; Smith, E. L.; more...
    Blood (2020)

    Fulltext@MSK | Save
  • Whole-genome sequencing reveals evidence of two biologically and clinically distinct entities: Progressive versus stable myeloma precursor disease
    Meeting Abstract

    Oben, B.; Froyen, G.; Maclachlan, K. H.; Zheng-Lin, B.; Yellapantula, V.; Abascal, F.; Leongamornlert, D. A.; Derkach, A.; Geerdens, E.; Diamond, B.; more...
    Blood (2020)

    Fulltext@MSK | Save
  • Copy number signatures predict chromothripsis and poor clinical outcome in newly diagnosed multiple myeloma patients
    Meeting Abstract

    Maclachlan, K. H.; Zheng-Lin, B.; Yellapantula, V.; Derkach, A.; Rustad, E. H.; Diamond, B.; Hultcrantz, M.; Dogan, A.; Zhang, Y.; Morgan, G.; more...
    Blood (2020)

    Fulltext@MSK | Save
  • The genomic complexity of multiple myeloma precursor disease can be predicted using copy number signatures on targeted sequencing and SNP array data
    Meeting Abstract

    Maclachlan, K. H.; Zheng-Lin, B.; Yellapantula, V.; Rustad, E. H.; Diamond, B.; Hultcrantz, M.; Dogan, A.; Zhang, Y.; Morgan, G.; Landgren, O.; more...
    Blood (2020)

    Fulltext@MSK | Save
  • Evaluation of minimal residual disease (MRD) negativity in patients with relapsed or refractory multiple myeloma treated in the CANDOR Study
    Meeting Abstract

    Landgren, O.; Weisel, K.; Dachs, L. R.; Moreau, P.; Turgut, M.; Hajek, R.; Mollee, P.; Kim, J. S.; Zhang, J.; Go, N.; more...
    Blood (2020)

    Fulltext@MSK | Save
  • Weekly carfilzomib, lenalidomide, dexamethasone and daratumumab (wKRd-D) combination therapy in newly diagnosed multiple myeloma: final results from a clinical and correlative phase 2 study
    Meeting Abstract

    Landgren, O.; Hultcrantz, M.; Lesokhin, A. M.; Mailankody, S.; Hassoun, H.; Tan, C.; Shah, U. A.; Lu, S. X.; Diamond, B.; Salcedo, M.; more...
    Blood (2020)

    Fulltext@MSK | Save
  • Assessment of minimal residual disease in a phase 1b study of once-weekly carfilzomib combined with lenalidomide and dexamethasone in patients with multiple myeloma
    Meeting Abstract

    Landgren, O.; Alsina, M.; Biran, N.; Vesole, D. H.; Wallace, P. K.; Fang, B.; Arnold, G.; Kimball, A.; Siegel, D. S.
    Blood (2020)

    Fulltext@MSK | Save
  • Association of patient activity bioprofiles with Hrqol and clinical responses: A prospective novel trial using mobile wearables in newly diagnosed multiple myeloma patients
    Meeting Abstract

    Korde, N.; Tavitian, E.; Derkach, A.; Zarski, A.; Salcedo, M.; Mailankody, S.; Hassoun, H.; Lesokhin, A. M.; Lendvai, N.; Smith, E. L.; more...
    Blood (2020)

    Fulltext@MSK | Save